Royce & Associates LP Halozyme Therapeutics, Inc. Transaction History
Royce & Associates LP
- $10.3 Billion
- Q4 2024
A detailed history of Royce & Associates LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 196,999 shares of HALO stock, worth $12.3 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
196,999
Previous 124,011
58.86%
Holding current value
$12.3 Million
Previous $7.09 Million
32.76%
% of portfolio
0.09%
Previous 0.07%
Shares
9 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$831 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$449 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$261 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$216 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.71B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...